The
slide to be stained for Progesterone Receptor (PR)
comprised:
| No. |
Tissue |
PR-positivity* |
PR-intensity* |
| 1. |
Breast ductal carcinoma |
Negative |
- |
| 2. |
Uterine cervix |
80-90% |
Moderate to strong |
| 3. |
Breast ductal carcinoma |
40-60% |
Moderate to strong |
| 4. |
Breast ductal carcinoma |
60-80% |
Moderate to strong |
| 5. |
Breast ductal carcinoma |
90-100% |
Strong |
*PR-status and staining
pattern was characterized by reference laboratories
using the mAb
clone PgR 636 and the rmAb clone 1E2.
Criteria for assessing a PR staining as optimal included:
- A moderate to
strong, distinct nuclear staining of
the columnar epithelial cells, the basal squamous epithelial
cells and the stromal cells in the uterine cervix.
- A moderate to strong, distinct nuclear
staining of the ductal breast carcinomas no. 3, 4 & 5 in
accordance with the PR status.
- No nuclear staining of the PR negative
ductal breast carcinoma no. 1 – only epithelial cells in
remnants of normal glands should show a positive reaction.
111 laboratories submitted stains. At the assessment 55 achieved
optimal marks (50%), 36 good (32%), 17 borderline (15 %) and 3 poor
marks (3 %).
The following Abs were used:
mAb clone PgR 636 (Dako, n=48; NeoMarkers/Thermo,
n=1)
mAb clone 16 (Novocastra/Leica, n=15; Monosan, n=1)
mAb clone 1A6 (Novocastra/Leica, n=4; BioCare, n=1; Zhongshan
Golden Bridge Biotechnology, n=1)
mAb clone PR-1 (ImmunoVision, n=2; Zytomed, n=1)
mAb clone PgR 1294 (Dako, n=2)
mAb clone PR 88 (BioGenex, n=1)
mAb clone hPRa 2 + hPRa 3 (NeoMarkers, n=1)
mAb clone cocktail 16/SAN 27 (Novocastra/Leica, n=1)
rmAb clone 1E2 (Ventana, n=29)
rmAb clone SP2 (NeoMarkers/ Thermo, n=4; DCS, n=1)
Optimal staining for PR in this assessment was only obtained with
the mAb clones PgR 636 (27 out of 49), PgR 1294 (1 out
of 2), 16 (14 out of 16), the mAb cocktail 16/SAN 27
(1 out of 1) and the rmAb 1E2 (12 out of 27).
All optimal protocols were based on heat induced epitope retrieval
(HIER) and the following main protocol settings:
PgR 636: The HIER buffers used were Tris-EDTA/EGTA pH 9.0
(11/20)*; Target Retrieval Buffer pH 9, (Dako) (6/9),
EDTA/EGTA pH 8 (1/2), Target Retrieval Solution pH 6.1 (Dako)
(2/3), Bond Epitope Retrieval Solution 2 (Bond, Leica)
(2/4), or Citrate pH 6.0 (5/10). The mAb was typically diluted in the
range of 1:50 – 1:600 depending on the total sensitivity of the
protocol employed or as a Ready-To-Use Ab. With these settings 40
out of 43 (93 %) laboratories produced a sufficient staining
(optimal or good).
PgR 1294: The HIER buffer used was a Citrate buffer pH 6.0
(1/2). The Ab was used as a Ready-To-Use Ab. With these settings 2
out of 2 (100 %) laboratories produced a sufficient staining
(optimal or good).
16: The HIER buffers used were Tris-EDTA/EGTA pH 9.0 (8/8);
Target Retrieval Buffer pH 9, (Dako) (2/2)*, Citrate pH 6.0
(2/2) or Cell Conditioning1 (BenchMark, Ventana) (2/3). The mAb
was typically diluted in the range of 1:50 – 1:500 depending on the
total sensitivity of the protocol employed. With these settings 14
out of 15 (93 %) laboratories produced a sufficient staining
(optimal or good).
16/SAN 27: The HIER buffer used was Tris-EDTA/EGTA pH 9.0
(1/1). The mAb was diluted 1:300.
1E2: The HIER buffer used were Cell Conditioning1 (BenchMark,
Ventana) (12/29). The mAb was used as a Ready-To-Use Ab (Ventana).
With these settings 26 out of 29 (90 %) laboratories produced a
sufficient staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
The most frequent causes of insufficient staining were:
- Too low concentration of the primary antibody
- Less successful primary antibody
- Insufficient epitope retrieval – too short efficient HIER time
- “Too sensitive” protocol settings (for the rmAbs SP2 and 1E2).
In this assessment (and in concordance with the
previous PR assessments run B2 & B4), the insufficient results were
caused by a false negative, a false positive staining or a staining
with a poor signal-to-noise ratio hampering the interpretation. A
too weak or false negative staining was seen in 9 out of 20 (55 %) of the
insufficient results, while in 7 out of 20 (35 %) a too
strong staining and false positive reaction was seen.
Virtually all laboratories could demonstrate PR in the ductal breast
carcinoma no. 5 (high expressor, 90-100 % positivity), whereas the prevalent feature of the insufficient
staining was a too weak or entirely false negative staining of the
ductal breast carcinoma no. 3 (low expressor, 40-60 % positivity).
Unexpectedly, 35 % of the insufficient results were due to a
false positive nuclear staining in the ductal breast carcinoma no.
1. The false positive reaction was mainly seen by protocols based on
the two rabbit monoclonal antibodies clone 1E2 (3 out of 27) and SP2
(2 out 5) but also with the mAb clone 1A6 (2 out 6). When a false
positive reaction was observed in the PR negative tumour also a
false positive nuclear reaction was seen in scattered non-epithelial
cells as lymphocytes and endothelial cells, and for the clone 1A6
also a diffuse cytoplasmic reaction was seen. No single parameter
causing the false positive reaction could by identified, but the
combination of efficient HIER, e.g., in pressure cooker, and usage of a
high Ab concentration seemed to be the main causes.
This was the fourth assessment of PR. Throughout, a
constant increase of the pass rate has been seen (table 1).
Table 1. Pass
rate for PR in four runs
Multiple factors may contribute to the improvement, but especially
the focus on the choice of Ab and an appropriate control such as
normal uterine cervix seem to be central parameters for an
improved demonstration of PR. Table 2 shows the cumulated pass rates
for the most widely used Abs in the 3 recent runs for PR, B2, B4 and
B6.
Table 2.
Cumulated pass rate for PR in three runs
| |
Total B2, B4 & B6 |
|
|
Protocols analyzed |
Sufficient |
|
mAb clone 1A6 |
17 |
8 (47%) |
|
mAb clone 16 |
51 |
40 (78%) |
|
mAb clone PgR 636 |
129 |
104 (81%) |
|
rmAb 1E3 |
57 |
52 (91%) |
|
rmAb SP2 |
16 |
7 (44%) |
From the table 2 it is clear that the 3 most widely used clones also
show the most successful performance in the three runs, which
statistically of course can be related to the difference in the
number of protocols analyzed for each Ab and does not implicit show
the exact performance of each of the Abs, when the protocol
parameters have been optimized for each individual Ab. However, the
data is in line with the results observed by UK NEQAS (Ibrahim M et al. Am J Clin Pathol
2008;129:398-409), where the pass rates for the clones PgR 636, 1A6
and SP2 were 85%, 40 % and 20%, respectively.
As described previously the uterine cervix seems to be an
appropriate control for the evaluation of the sensitivity of the PR
staining. In an optimal protocol almost all the columnar epithelial
cells, the basal squamous epithelial cells and the stromal cells
must show a strong and distinct nuclear staining with only a
minimal cytoplasmic reaction. However, differences are seen depending
on the Ab selected. When using the mAb clone 1A6, the basal squamous
epithelial cells are negative and a cytoplasmic reaction is seen in
the intermediate and superficial squamous epithelial cells, while
the clone PgR 636 gives an intense cytoplasmic reaction in the
columnar epithelial cells.
Conclusion
The mAb clones PgR 636, 16 and the rmAb clone 1E3
are all well performing and robust Abs for PR. HIER is mandatory.
The concentration of the Ab must be carefully calibrated on an
appropriate control such as the uterine cervix. |